SUGARNSALT Trial

The OHSU Harold Schnitzer Diabetes Center, under the leadership of Dr. Rodica Busui, MD, PhD, is participating in this multicenter clinical trial funded by Breakthrough T1D and the Canadian Institutes of Health Research. The goal of this study is to determine whether a medication called sotagliflozin (SOTA) can help slow the progression of kidney function decline in people with type 1 diabetes. SOTA is a drug in the family of medications called SGLT1 and SGLT2 inhibitors and is currently FDA-approved to reduce the risk of being admitted to the hospital due to heart failure. Some studies have shown that drugs like SOTA may also slow the progression of kidney disease in people with and without diabetes.

The total time that you will be in this study is about 3 years and 4 months. You will be compensated for your participation in the study for a total of $900 once you complete all study visits.

Key Eligibility Criteria:

• Are 18 years or older
• Diagnosed with type 1 diabetes for at least 8 years & continuously treated with insulin
• Have been told by your doctor that you have diabetic kidney disease or protein in your urine

If you are interested or would like more information, please contact the study team at 971-610-3005 or email sugarnsalt@ohsu.edu.

OHSU IRB# 27158

TINSAL-FISH Trial

The OHSU Harold Schnitzer Diabetes Center (PI: Dr. Rodica Busui, MD PhD) is part of a multicenter trial funded by the National Institute of Health to identify new therapies that could reverse diabetic neuropathy, a very common and challenging complication of diabetes that leads to nerve damage and loss. The trial is evaluating whether fish oil, alone and in combination with salsalate, a drug approved to treat arthritis may be effective to treat diabetic peripheral neuropathy, and identify new targets that could be tested in a future trial. This study is being conducted at the University of Iowa, at the University of Michigan, and Oregon Health and Sciences University (OHSU).

You will be compensated for your participation in the study for a total of $300 once you complete all study visits.

Key Eligibility Criteria:

• Are 18 years or older
• Have type 2 diabetes
• Have an HbA1c at screening less than 9.5%

Duration: About 6 months.

If you are interested or would like more information, please contact the study team at 971-484-5758 or 971-610-3005 or email tinsalfish@ohsu.edu.

OHSU IRB# 27479

TWIIST-T2D Trial

The OHSU Harold Schnitzer Diabetes Center, under the leadership of Dr. Rodica Busui, MD, PhD, is participating in this multicenter clinical trial funded by Sequel Med Tech and DEKA Research & Development Corp. The goal of this study is to learn if a new investigational device that automates the delivery of insulin can safely control blood sugar levels in people with type 2 diabetes. This is called an automated insulin delivery (AID) system or the “twiist” system. The system includes an insulin pump, an Abbott continuous glucose monitor (CGM), and a computer program algorithm. The CGM measures your blood sugar level and sends this information to the pump. A computer program on the pump determines how much insulin should be given.

The total time that you will be in this study is about 4 months. You will be compensated for your participation in the study for a total of $925 once you complete all study visits.

Key Eligibility Criteria:

• Are 18 years or older
• Diagnosed with type 2 diabetes for at least 6 months
• Currently using an insulin pump without automation or taking multiple daily injections as your insulin regimen

If you are interested or would like more information, please contact the study team at 971-291-9594 or email twiist@ohsu.edu.

OHSU IRB# 28493

PRECIDENTD Trial

The OHSU Harold Schnitzer Diabetes Center, under the leadership of Dr. Rodica Busui, MD, PhD, is participating in this multicenter clinical trial funded by Patient-Centered Outcomes Research Institute (PCORI). The goal of this study is to learn more about the only two classes of diabetes medications (GLP-1 & SGLT2i) shown to reduce the risk of heart and kidney disease for people with type 2 diabetes, since people with type 2 diabetes are twice as likely to have heart disease or suffer a stroke compared to someone who does not have diabetes. Both mediation classes are effective in reducing the risk of heart or kidney disease in people with type 2 diabetes, however, the study aims to understand which medication class is better suited to different populations within type 2 diabetes.

The total time that you will be in this study is about 4 years. For each year that you participate in the study and complete each year’s visits, you will be compensated $500 annually through 2029.

Key Eligibility Criteria:

• Diagnosed with type 2 diabetes
• Age 40 years or older where:
  • Over age 40 and have had a heart attack, stroke, or stents to open their blood vessels
  • Over age 60 with an Hb1c >8, or who smoke

If you are interested or would like more information, please contact the study team at 971-509-4222 or email precidentd@ohsu.edu.

OHSU IRB# 28069

REIMAGINE Trial

The OHSU Harold Schnitzer Diabetes Center, under the leadership of Dr. Rodica Busui, MD, PhD, is participating in this multicenter clinical trial funded by Novo Nordisk. The goal of this study is to determine the effects and safety of a new investigational product called CagriSema. CagriSema is a combination of cagrilintide and semaglutide. The study aims to determine whether weekly subcutaneous injections of CagriSema vs. Placebo (a ‘dummy’ medicine) can help people living with both type 2 diabetes and painful diabetic peripheral neuropathy, by looking at nerve pain.

The total time that you will be in this study is about 10 months. You will be compensated for your participation in the study for a total of $925 once you complete all study visits.

Key Eligibility Criteria:

• Age 18 years and older
• Diagnosed with type 2 diabetes for at least 6 months
• You have painful diabetic neuropathy (burning pain, numbness, tingling, usually worse at night) and rate your pain as a 4/10 daily

If you are interested or would like more information, please contact the study team at 971-291-9594 or email nn93887864@ohsu.edu.

OHSU IRB# 28088